Kingswood Wealth Advisors LLC Has $3.98 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Kingswood Wealth Advisors LLC lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 144.9% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 35,735 shares of the biopharmaceutical company's stock after purchasing an additional 21,144 shares during the quarter. Kingswood Wealth Advisors LLC's holdings in Gilead Sciences were worth $3,983,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of GILD. Brighton Jones LLC grew its position in Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock valued at $1,326,000 after acquiring an additional 2,450 shares during the period. Everhart Financial Group Inc. bought a new stake in shares of Gilead Sciences during the fourth quarter worth $239,000. Principal Securities Inc. grew its holdings in shares of Gilead Sciences by 45.0% during the fourth quarter. Principal Securities Inc. now owns 14,404 shares of the biopharmaceutical company's stock worth $1,330,000 after purchasing an additional 4,468 shares during the last quarter. Allworth Financial LP grew its holdings in shares of Gilead Sciences by 24.8% during the fourth quarter. Allworth Financial LP now owns 35,953 shares of the biopharmaceutical company's stock worth $3,345,000 after purchasing an additional 7,143 shares during the last quarter. Finally, J.W. Cole Advisors Inc. grew its holdings in shares of Gilead Sciences by 1.0% during the fourth quarter. J.W. Cole Advisors Inc. now owns 13,597 shares of the biopharmaceutical company's stock worth $1,256,000 after purchasing an additional 135 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Trading Down 2.6%

Shares of Gilead Sciences stock opened at $108.00 on Wednesday. The business has a fifty day simple moving average of $105.88 and a two-hundred day simple moving average of $102.49. Gilead Sciences, Inc. has a 1 year low of $62.69 and a 1 year high of $119.96. The company has a market capitalization of $134.34 billion, a price-to-earnings ratio of 22.74, a P/E/G ratio of 0.72 and a beta of 0.29. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.04. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The business had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same quarter last year, the firm posted ($1.32) EPS. The company's quarterly revenue was down .3% on a year-over-year basis. Research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.93%. The ex-dividend date is Friday, June 13th. Gilead Sciences's dividend payout ratio is currently 66.53%.

Analyst Upgrades and Downgrades

GILD has been the topic of several recent research reports. Wells Fargo & Company raised their price target on Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Bank of America raised their price target on Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a report on Wednesday, March 5th. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a report on Wednesday, May 21st. JPMorgan Chase & Co. raised their price target on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Finally, Morgan Stanley raised their price target on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Nine research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $110.55.

Insider Transactions at Gilead Sciences

In related news, insider Johanna Mercier sold 3,000 shares of the business's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $110.17, for a total value of $330,510.00. Following the completion of the transaction, the insider now owns 120,168 shares of the company's stock, valued at $13,238,908.56. The trade was a 2.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction dated Friday, May 30th. The shares were sold at an average price of $110.42, for a total value of $1,104,200.00. Following the completion of the transaction, the chief executive officer now directly owns 620,268 shares of the company's stock, valued at approximately $68,489,992.56. This trade represents a 1.59% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 48,500 shares of company stock valued at $5,236,245. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.